A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER [extended release] can reverse the increased bladder wall thickness in patients with overactive bladder

Trial Profile

A multi-centre, randomised, placebo controlled, double blind, parallel group study in female patients to evaluate whether tolterodine ER [extended release] can reverse the increased bladder wall thickness in patients with overactive bladder

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Nov 2005

At a glance

  • Drugs Tolterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top